更新于：2024-11-01

Pancreatitis, Chronic

慢性胰腺炎

更新于：2024-11-01

基本信息

别名

CP - Chronic pancreatitis、Chronic Pancreatitis、Chronic pancreas inflammation

+ [37]

简介

INFLAMMATION of the PANCREAS that is characterized by recurring or persistent ABDOMINAL PAIN with or without STEATORRHEA or DIABETES MELLITUS. It is characterized by the irregular destruction of the pancreatic parenchyma which may be focal, segmental, or diffuse.

关联

项与慢性胰腺炎相关的药物

Autologous pancreatic islets (Koligo)

靶点-

作用机制

细胞替代物

在研机构

Koligo Therapeutics, Inc.初创企业

原研机构

Koligo Therapeutics, Inc.初创企业

在研适应症

慢性胰腺炎

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2018-08-22

Pancrelipase(Eurand)

胰脂肪酶(Eurand)

靶点-

作用机制

胰酶替代物

在研机构

Viokace LLC [+1]

原研机构

Allergan Ltd. (Ireland)

在研适应症

胰腺外分泌功能不全

非在研适应症

囊性纤维化 [+2]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2009-08-27

Pancrelipase(AbbVie, Inc.)

胰酶(AbbVie, Inc.)

靶点-

作用机制

胰酶替代物

在研机构

Abbott Laboratories GmbH [+1]

原研机构

AbbVie, Inc.

在研适应症

消化不良 [+1]

非在研适应症

腹部膨胀 [+5]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2009-04-30

433

项与慢性胰腺炎相关的临床试验

NCT05270434 / Not yet recruitingN/AIIT

Optimal Timing of Endoscopic Intervention After Extracorporeal Shock-Wave Lithotripsy in the Treatment of Chronic Pancreatitis with Pancreatic Stones.

This study aims to determine the optimal timing of endoscopic intervention after extracorporeal shock wave lithotripsy(ESWL) of chronic pancreatitis with pancreatic stones.

开始日期2024-11-01

申办/合作机构

海军军医大学第一附属医院

NCT06655051 / Not yet recruitingN/AIIT

Efficacy and Safety of Single Plastic Stent Compared with Fully Covered Self-Expanding Metal Stent on Benign Biliary Stricture Secondary to Chronic Pancreatitis: a Single Center，Prospective，Non-inferiority, Open Label, Randomized, Controlled Trial

The goal of this clinical trial is to compare the efficacy and safety of a single plastic stent versus a fully covered self-expanded metal stent in relieving benign biliary stricture secondary to chronic pancreatitis. The main questions it aims to answer is:
Whether the efficacy of a single plastic stent is non-inferior to that of a fully covered metal stent in patients with benign biliary stricture secondary to chronic pancreatitis？
Participants will be randomly assigned to receive either a single plastic stent (SPS) placement or fully covered self-expanded metal stent placement treatment for 6 months, and they will be followed up for 18 months.

开始日期2024-11-01

申办/合作机构

海军军医大学第一附属医院

NCT04760847 / Not yet recruitingN/AIIT

Intermittent Fasting as a Primary Means for Improving Quality of Life for Acute and Chronic Pancreatitis

The purpose of this research is to compare intermittent fasting with a standard diet approach for improving the quality of life related to your pancreas disease. Our hope is to improve your symptoms and prevent you from needing to go into the hospital for pancreas-related issues.

开始日期2024-10-01

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

100 项与慢性胰腺炎相关的临床结果

登录后查看更多信息

100 项与慢性胰腺炎相关的转化医学

登录后查看更多信息

0 项与慢性胰腺炎相关的专利（医药）

登录后查看更多信息

27,878

项与慢性胰腺炎相关的文献（医药）

2025-04-01·DEN Open

Image J as the quantification tool in endosonography strain elastography may be reflected in the disturbance of endocrine pancreatic dysfunction

Article

作者: Iwakiri, Katsuhiko ; Nakamura, Ken ; Futagami, Seiji ; Watanabe, Yoshiyuki ; Ueki, Nobue ; Kawawa, Rie ; Onda, Takeshi ; Agawa, Shuhei ; Tanabe, Tomohide ; Habiro, Mayu ; Kirita, Kumiko

AbstractObjectivesPancreatic fibrosis is one of the main pathological features of chronic pancreatitis (CP), suggesting a strong relationship between CP and pancreatic ductal cancer. There was no available data about pancreatic fibrosis and pancreatic dysfunction in the early CP (ECP) using endosonography (EUS).MethodsAsymptomatic patients with pancreatic enzyme abnormalities (AP‐P; n = 56) and patients with ECP (n = 21) were determined by the absence of abnormal findings on upper gastrointestinal endoscopy, abdominal ultrasonography, and abdominal computed tomography. An Olympus EUS (GF‐UCT 260; Olympus) was used to perform EUS. Open software “Image J”, developed by NIH, was used to measure the surface area fraction of the designated elastic blue region. The maximum value among the pancreatic head, pancreatic body, and pancreatic tail was defined as the ELST‐blue score. The exocrine and endocrine pancreatic functions were evaluated using the N‐benzoyl‐l‐tyrosyl‐p‐aminobenzoic acid (BT‐PABA) test and homeostasis model assessment of β‐cell function (HOMA‐β) value, respectively.ResultsEUS score, lobularity, and hyperechoic foci/strands in patients with ECP were significantly (p < 0.001) higher than those in patients with AP‐P. In addition, there were no significant differences in the BT‐PABA test (73.1 ± 25.5, 68.5 ± 15.6) and HOMA‐β (93.1 ± 67.4, 73.5 ± 139.7) between patients with ECP and AP‐P. The ELST‐blue score measured by image J as the quantification tool in EUS strain elastography in patients with ECP was significantly higher (p = 0.002) than that in patients with AP‐P. Interestingly, the ELST‐blue score was significantly associated with HOMA‐β in patients with ECP.ConclusionsThe ELST‐blue score may be a useful tool for the evaluation of endocrine pancreatic dysfunction in the ECP.

2025-04-01·DEN Open

Immunoglobulin G4 ‐related gastrointestinal disease associated with type 1 autoimmune pancreatitis: A case report

作者: Eto, Hiroyuki ; Arai, Motonori ; Nagashima, Ariki ; Sato, Shingo ; Okamoto, Shikiko ; Shimazaki, Reiri ; Nitta, Hiroshi ; Kasai, Toyotaka ; Ito, Hiroshi ; Ushiyama, Rui

AbstractImmunoglobulin G4 (IgG4)‐related diseaseis a systemic inflammatory condition of unknown etiology characterized by increases in serum IgG4 and in the number of IgG4‐positive cells in affected tissues. One of the commonly involved locations is the pancreas; this condition is known as type 1 autoimmune pancreatitis (AIP). Type 1 AIP, which shows a biliary stricture in the intrapancreatic bile duct, can be misdiagnosed as a malignancy due to similar cholangiography findings and clinical presentation. In rare cases complicated by post‐bulbar duodenal ulcers, differentiating between type 1 AIP and malignancies is even more difficult. An 81‐year‐old male was referred to our hospital for the treatment of a pancreatic head mass and obstructive jaundice. Serological and radiological findings were consistent with both type 1 AIP and a malignancy. Gastroduodenoscopy revealed a post‐bulbar duodenal ulcer with endoscopic features that evoked malignant duodenal invasion. Although biopsies were negative for malignant cells, subsequent bleeding from the lesion suggested the progression of malignancy, which led to surgical resection. Pancreatoduodenectomy and pathological examination indicated that type 1 AIP was present. Simultaneously, the involvement of IgG4‐related disease in the ulcerative lesion was suggested. To our knowledge, this is the first reported case of type 1 AIP complicated by post‐bulbar duodenal ulcers, which was misdiagnosed as malignancy and considered an IgG4‐related gastrointestinal disease associated with type 1 AIP.

2025-04-01·DEN Open

Diagnostic accuracy of endoscopic ultrasonographic shear wave elastography for assessing early chronic pancreatitis using the Japanese diagnostic criteria 2019

Article

作者: Eguchi, Takaaki ; Hiroe, Kosuke ; Tsuji, Yoshihisa ; Inatomi, Osamu ; Okamoto, Takuya ; Kimura, Hidenori ; Nishida, Atsushi ; Inoue, Akitoshi ; Andoh, Akira ; Tomozawa, Yuki ; Shintani, Shuhei ; Watanabe, Yoshiyuki

AbstractBackground and AimEndoscopic ultrasound shear wave elastography (EUS‐SWE) can facilitate an objective evaluation of pancreatic fibrosis. Although it is primarily applied in evaluating chronic pancreatitis, its efficacy in assessing early chronic pancreatitis (ECP) remains underinvestigated. This study evaluated the diagnostic accuracy of EUS‐SWE for assessing ECP diagnosed using the Japanese diagnostic criteria 2019.MethodsIn total, 657 patients underwent EUS‐SWE. Propensity score matching was used, and the participants were classified into the ECP and normal groups. ECP was diagnosed using the Japanese diagnostic criteria 2019. Pancreatic stiffness was assessed based on velocity (Vs) on EUS‐SWE, and the optimal Vs cutoff value for ECP diagnosis was determined. A practical shear wave Vs value of ≥50% was considered significant.ResultsEach group included 22 patients. The ECP group had higher pancreatic stiffness than the normal group (2.31 ± 0.67 m/s vs. 1.59 ± 0.40 m/s, p < 0.001). The Vs cutoff value for the diagnostic accuracy of ECP, as determined using the receiver operating characteristic curve, was 2.24m/s, with an area under the curve of 0.82 (95% confidence interval: 0.69–0.94). A high Vs was strongly correlated with the number of EUS findings (rs = 0.626, p < 0.001). Multiple regression analysis revealed that a history of acute pancreatitis and ≥2 EUS findings were independent predictors of a high Vs.ConclusionsThere is a strong correlation between EUS‐SWE findings and the Japanese diagnostic criteria 2019 for ECP. Hence, EUS‐SWE can be an objective and invaluable diagnostic tool for ECP diagnosis.

209

项与慢性胰腺炎相关的新闻（医药）

2024-10-04

·PipelineReview

Triveni Bio Raises $115 Million Series B Financing to Expand Pipeline of Therapeutics Addressing Immunological and Inflammatory (I&I) Disorders

— Series B led by Goldman Sachs Alternatives with participation from Fidelity Management & Research Company, Deep Track Capital, and existing investors — — Funding will advance second-generation anti-kallikrein 5/7+IL-13 bispecific (TRIV-573) through clinical proof-of-concept — — Lead antibody program TRIV-509 IND submission on track for 1Q 2025 — WATERTOWN, MA, USA I October 2, 2024 I Triveni Bio Inc., a biotech company advancing novel antibody treatments for I&I disorders, today announced a $115 million Series B to support pipeline expansion. The round was led by Goldman Sachs Alternatives with significant participation from additional new investors Fidelity Management & Research Company and Deep Track Capital, and Series A investors Atlas Venture, Cormorant Asset Management, OrbiMed, Viking Global Investors, and Invus. “We have built a differentiated pipeline of novel drug targets,” said Vishal Patel, Ph.D., Chief Executive Officer of Triveni Bio. “The Series B accelerates our pipeline expansion, particularly for our bispecific program, TRIV-573, which uniquely combines two orthogonal mechanisms of action.” The Series B financing follows a $92 million Series A completed less than a year ago. In addition to pipeline advancement, Triveni is expanding its data science platform with a focus on precision dermatology and strengthening its leadership team – most recently with the appointment of Bhaskar Srivastava, M.D., Ph.D., as Chief Medical Officer. “We have been impressed with the team’s progress towards becoming a clinical stage organization for I&I disorders where standard of care is lacking,” said Josh Richardson M.D., Managing Director within Goldman Sachs Alternatives. “We look forward to supporting both programs through clinical proof-of-concept and beyond.” Triveni plans to submit an Investigational New Drug (IND) application for its lead candidate, TRIV-509, in the first quarter of 2025. TRIV-509 is a monoclonal antibody inhibitor targeting kallikreins 5 and 7 (KLK 5/7) that has demonstrated superior efficacy compared to IL-4R inhibition in multiple preclinical atopic dermatitis models. TRIV-573 combines KLK 5/7 inhibition with a well-established IL-13 mechanism. Triveni continues to explore additional innovative combinations to further enhance treatment outcomes. The company is also advancing an antibody inhibitor of trypsin 1 and 2 for the treatment of hereditary pancreatitis, a genetic disorder predominantly caused by PRSS1 mutations. Hereditary pancreatitis, which currently has no approved treatments, impacts around 10,000 individuals in the United States. About Triveni Bio Triveni Bio is a biotechnology company at the forefront of novel antibody-based therapies for immunological and inflammatory disorders. Using a genetics-informed, precision medicine approach, the company seeks to establish proof-of-concept early in the drug development process by leveraging deep insights into genetic and mechanistic biology. To learn more, visit www.triveni.bio . SOURCE: Triveni Bio

高管变更临床申请

2024-10-03

·药明康德

不到一年完成两次约1亿美元融资！新锐扩大免疫和炎症管线；推进变构小分子进入临床，新锐获约4300万美元A轮融资

▎药明康德内容团队编辑扩大免疫和炎症（I&I）管线，新锐获超1亿美元B轮融资 Triveni Bio今天宣布完成1.15亿美元的B轮融资，以支持其旗下I&I管线扩展。此轮融资由Goldman Sachs Alternatives领投，其他新投资者包括Fidelity Management & Research Company和Deep Track Capital，A轮投资者Atlas Venture、Cormorant Asset Management、OrbiMed、Viking Global Investors和Invus也参与其中。值得一提的是，Triveni Bio在不到一年前时完成了一项总额达9200万美元的A轮融资。此次所获得的资金，除了用于推进旗下管线外，Triveni Bio还将扩展其数据科学平台，尤其聚焦于精准皮肤病学，并同时加强其领导团队。该公司计划于2025年第一季度为其主打药物TRIV-509提交IND申请。TRIV-509是一种针对激肽释放酶5和7（KLK 5/7）的单克隆抗体抑制剂，在多种临床前特应性皮炎模型中，与IL-4R抑制剂相比，展现更佳的疗效。另一个管线TRIV-573则为抑制KLK 5/7与IL-13的双重抑制剂。该公司还在推进胰蛋白酶1和2抗体抑制剂TRIV-920的研发，用于治疗遗传性胰腺炎，这是一种主要由PRSS1突变引起的遗传性疾病。遗传性胰腺炎目前尚无获美国FDA批准的治疗方法。推进变构小分子进入临床！新锐获约4300万美元A轮融资 LoQus23 Therapeutics今天宣布成功完成3500万英镑（约4300万美元）的A轮融资。此轮融资由Forbion领投，现有投资者包括SV Health Investors的Dementia Discovery Fund（DDF）和Novartis Venture Fund（NVF）也参与其中。 LoQus23成立于2019年，由DDF企业家David Reynolds博士、Caroline Benn博士和Ruth McKernan博士共同创立，由SV痴呆症发现基金提供种子轮融资。该公司于2021年从NVF获得了额外的种子轮融资。此后，该公司建立了一个检测平台和开发一系列MutSα和MutSβ小分子抑制剂，这些抑制剂可潜在治疗多达30种三联体重复疾病（triplet repeat diseases），包括亨廷顿病。这次A轮融资所得将主要用于支持LoQus23的主打项目变构小分子MutSβ抑制剂的临床前开发和初步临床研究。该公司预计该项目于2026年进入临床，用以治疗亨廷顿病。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料： [1] Triveni Bio Raises $115 Million Series B Financing to Expand Pipeline of Therapeutics Addressing Immunological and Inflammatory (I&I) Disorders. Retrieved October 2, 2024 from https://triveni.bio/triveni-bio-raises-usd115-million-series-b-financing-to-expand-pipeline-of-therapeutics-addressing-immunological-and-inflammatory-i-and-i-disorders/ [2] Science and Pipeline. Retrieved October 2, 2024 from https://triveni.bio/science-and-pipeline/ [3] LoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington’s disease. Retrieved October 2, 2024 from https://loqus23.com/loqus23-therapeutics-announces-35-million-c-43-million-series-a-financing-to-advance-its-small-molecule-somatic-expansion-inhibition-therapy-for-huntingtons-disease/ 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床申请临床研究

2024-10-02

·EndPoints

Triveni to take experimental eczema drug to the clinic, backed by new $115M financing round

On Wednesday, Triveni Bio became the latest immunology and inflammation startup this year to announce a $100 million-plus financing round. Money has come thick and fast to I&I companies this year, and Triveni’s Series B comes less than a year after it announced a $92 million Series A. The new round was led by Goldman Sachs and included Fidelity, Deep Track Capital and other previous investors in the company, like Atlas Venture and OrbiMed. With the raise, Triveni will fund its lead experimental eczema antibody drug, TRIV-509, and plans to ask the FDA to let it start clinical trials of its lead program in the first quarter of 2025. That study will be in healthy volunteers, medical chief Bhaskar Srivastava told Endpoints News , and the company is seeking to develop the asset for atopic dermatitis, or eczema. Srivastava joined the company in June, leaving his post as SVP of clinical development at Nimbus Therapeutics. TRIV-509 targets kallikreins 5 and 7, and is involved in what’s called barrier dysfunction — when the skin can’t act as a proper protector from allergens and other irritants in people with atopic dermatitis. Triveni CEO Vishal Patel described barrier dysfunction as a hallmark feature of atopic dermatitis, as well as inflammation. “The barrier part, in particular, is novel because that is a unique part of that atopic dermatitis vicious cycle that really hasn’t been prosecuted in the past,” Patel told Endpoints. The company is also working on a follow-on compound called TRIV-573 that combines kallikrein 5/7 inhibition with IL-13, a well-known target (one of Dupixent’s targets). Triveni’s third program is an antibody treatment for hereditary pancreatitis.

高管变更